The FDA has approved Rybelsus, the first oral GLP-1 receptor agonist, for managing cardiovascular risks in adults. This medication, previously for typ
The FDA has approved Rybelsus, the first oral GLP-1 receptor agonist, for managing cardiovascular risks in adults. This medication, previously for type 2 diabetes, now offers a needle-free option to reduce inflammation and oxidative stress, protectin... [5710 chars]
